These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30715158)

  • 1. Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Allenbach Y; Bolko L; Toquet S; Landon-Cardinal O; Benveniste O
    Brain; 2019 Mar; 142(3):e9. PubMed ID: 30715158
    [No Abstract]   [Full Text] [Related]  

  • 2. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Papadopoulou C; Hong Y; Omoyinmi E; Brogan PA; Eleftheriou D
    Brain; 2019 Mar; 142(3):e8. PubMed ID: 30715143
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib.
    Fischer K; Aringer M; Steininger J; Heil J; Beissert S; Abraham S; Günther C
    Br J Dermatol; 2022 Sep; 187(3):432-435. PubMed ID: 35318646
    [No Abstract]   [Full Text] [Related]  

  • 4. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
    Kim H; Dill S; O'Brien M; Vian L; Li X; Manukyan M; Jain M; Adeojo LW; George J; Perez M; Grom AA; Sutter M; Feldman BM; Yao L; Millwood M; Brundidge A; Pichard DC; Cowen EW; Shi Y; Lu S; Tsai WL; Gadina M; Rider LG; Colbert RA
    Ann Rheum Dis; 2021 Mar; 80(3):406-408. PubMed ID: 32843325
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis.
    Mastrolia MV; Orsini SI; Marrani E; Maccora I; Pagnini I; Simonini G
    Clin Exp Rheumatol; 2023 Mar; 41(2):402-403. PubMed ID: 36861743
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK inhibitors in autoinflammation.
    Hoffman HM; Broderick L
    J Clin Invest; 2018 Jul; 128(7):2760-2762. PubMed ID: 29889100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
    Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
    Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib.
    Allenbach Y; Toquet S; Landon-Cardinal O; Benveniste O
    Brain; 2018 Nov; 141(11):e81. PubMed ID: 30335129
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
    Kim H; Brooks KM; Tang CC; Wakim P; Blake M; Brooks SR; Montealegre Sanchez GA; de Jesus AA; Huang Y; Tsai WL; Gadina M; Prakash A; Janes JM; Zhang X; Macias WL; Kumar P; Goldbach-Mansky R
    Clin Pharmacol Ther; 2018 Aug; 104(2):364-373. PubMed ID: 29134648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of anti-tumor necrosis factor-α antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis.
    Imafuku S; Maeyama A
    J Dermatol; 2021 May; 48(5):e240-e241. PubMed ID: 33745215
    [No Abstract]   [Full Text] [Related]  

  • 11. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A child with severe juvenile dermatomyositis treated with ruxolitinib.
    Aeschlimann FA; Frémond ML; Duffy D; Rice GI; Charuel JL; Bondet V; Saire E; Neven B; Bodemer C; Balu L; Gitiaux C; Crow YJ; Bader-Meunier B
    Brain; 2018 Nov; 141(11):e80. PubMed ID: 30335130
    [No Abstract]   [Full Text] [Related]  

  • 13. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
    J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
    Wong GN; Lee S; Foley P
    Australas J Dermatol; 2019 Nov; 60(4):e334-e335. PubMed ID: 31012089
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to letter to the editor: baricitinib and toxicity is a rare occurrence.
    Peng L; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Oct; 19(10):1371-1372. PubMed ID: 32804556
    [No Abstract]   [Full Text] [Related]  

  • 16. [Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)].
    Alten R; Nitschmann S
    Internist (Berl); 2017 Dec; 58(12):1341-1344. PubMed ID: 29119202
    [No Abstract]   [Full Text] [Related]  

  • 17. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1).
    Meesilpavikkai K; Dik WA; Schrijver B; Nagtzaam NMA; Posthumus-van Sluijs SJ; van Hagen PM; Dalm VASH
    J Allergy Clin Immunol; 2018 Jul; 142(1):328-330.e2. PubMed ID: 29729898
    [No Abstract]   [Full Text] [Related]  

  • 18. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
    Tuttle KR; Brosius FC; Adler SG; Kretzler M; Mehta RL; Tumlin JA; Tanaka Y; Haneda M; Liu J; Silk ME; Cardillo TE; Duffin KL; Haas JV; Macias WL; Nunes FP; Janes JM
    Nephrol Dial Transplant; 2018 Nov; 33(11):1950-1959. PubMed ID: 29481660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
    Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
    J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
    Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
    Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.